|
|
MindBio scientist's sleep research published in prestigious peer reviewed scientific journalMindBio's proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing VANCOUVER, BC / ACCESSWIRE / April 23, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6,... Lire le communiqué |
|
| |
|
| |
|
|
MindBio scientist's sleep research published in prestigious peer reviewed scientific journalMindBio's proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep the day after microdosing VANCOUVER, BC / ACCESSWIRE / April 23, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6,... Lire le communiqué |
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / April 16, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio" is pleased to announce Riverfort Global Opportunities PCC Ltd has requested to convert CAD$100,000 of its loan to 2,000,000 MindBio shares "Shares" at $0.05 per Share. All Shares will be subject to a hold period of fourmonths and one day from the... Lire le communiqué |
|
| |
|
| |
|
|
First doses of MB22001 administered in Phase 2B takehome trial in patients with Major Depressive Disorder.Follows successful Phase 2A trial where 53% of depressed patients were in complete remission from their depression at week 8 marked by a mean 14.1 point drop in MADRS score MontgomeryAsberg Depression Rating Scale, a 60% mean drop in depressive symptoms.VANCOUVER, BC / ACCESSWIRE / March 20,... Lire le communiqué |
|
| |
|
| |
|
|
First doses of MB22001 administered in Phase 2B takehome trial in patients with Major Depressive Disorder.Follows successful Phase 2A trial where 53% of depressed patients were in complete remission from their depression at week 8 marked by a mean 14.1 point drop in MADRS score MontgomeryAsberg Depression Rating Scale, a 60% mean drop in depressive symptoms.VANCOUVER, BC / ACCESSWIRE / March 20,... Lire le communiqué |
|
| |
|
| |
|
|
Ethics and regulatory approvals finalized for worldfirst takehome use of a psychedelic medicine MB22001 in placebocontrolled trial in depressed patients n=90Recruitment of clinical trial participants underwayFollows successful Phase 2a trial where 53% of depressed patients in complete remission at week 8 of treatmentPrior trials of MB22001 show statistically significant improvemen... Lire le communiqué |
|
| |
|
| |
|
|
MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8week, world first takehome trialRapid, robust, and clinically significant reduction in depression symptomsPrimary efficacy endpoint achieved with an impressive mean 14.1 point drop in MontgomeryAsberg Depression Rating Scale "MADRS" scoreAfter just 8 weeks, patients... Lire le communiqué |
|
| |
|
| |
